Happy #IndependenceDay from Rallybio! Wishing you a safe 4th of July as we celebrate the spirit of freedom and independence. #July4
About us
We are making science’s hardest obstacles our highest priority. Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward as we strive to develop and deliver the truly transformational. Read our Community Guidelines here: https://bit.ly/RLYBCGs
- Website
-
https://rallybio.com/
External link for Rallybio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New Haven, Connecticut
- Type
- Public Company
- Specialties
- Rare Disease
Locations
-
Primary
234 Church Street
Suite 1020
New Haven, Connecticut 06510, US
-
400 Farmington Ave
Suite R2818
Farmington, CT 06032, US
Employees at Rallybio
Updates
-
Did you know that June is Myasthenia gravis (MG) awareness month? MG is a chronic autoimmune disease that causes weakness in the body's voluntary muscles. Our team at Rallybio is committed to raising awareness of the challenges and opportunities faced by those who battle rare diseases like myasthenia gravis every day. #myastheniagravis #MG
-
Happy Pride from Rallybio! June is a time to celebrate the progress that has been made and look forward to the work that remains to ensure queer people feel valued and seen in their workplaces and beyond. #Pride #HappyPride
-
-
This #Juneteenth, we at Rallybio invite our colleagues, partners, and stakeholders to join us in reaffirming our commitment to creating a better future for all. Today, we reflect on the impact racial injustice and inequality have had on our history and how we can create lasting change. The Rallybio team is committed to advancing #healthequity and honoring the legacy of those who have fought for freedom, justice, and equality.
-
A report released earlier this month showed the United States continues to have a higher rate of maternal mortality across pregnancy, childbirth and postpartum compared with other high-income nations. According to the report, there were ~22 maternal deaths for every 100,000 live births in the United States in 2022 (the most recent year for which data was available). That rate was more than double, sometimes triple, those seen in most other high-income countries that year. The time to prioritize the health of women and babies is now, and preventative testing for rare diseases like #FNAIT is just the beginning of the work to be done. Read more from CNN here: https://lnkd.in/gacJkq5Q
-
Happy #FathersDay from our team at Rallybio to all of the dads out there who continue to inspire and make an impact every day!
-
-
Next week our co-founder Martin Mackay heads to the Longwood Healthcare Leaders Spring MIT forum to discuss driving productivity in R&D! Still need to register? Click the link below and #savethedate: June 17-18, 2024. https://lnkd.in/exxKDits
-
Rallybio reposted this
It’s encouraging to see major bodies like the U.S. Preventive Services Task Force issuing increased screening guidance in women’s health. New recommendations advise women to get a mammogram every other year starting at age 40, a response to rising cancer rates among women in their 40s and evidence that earlier screenings help save lives. The group estimated that its new recommendations could save up to 20% more lives relative to the old guidance, demonstrating the transformative impact that a stronger focus on preventative care can have on women’s health. At Rallybio, we are fierce advocates for women’s health, and there is no better time to discuss screening and preventative care than now as we close out this #WomensHealthMonth. For pregnant women in particular, receiving the right test at the right time could have life-changing impacts on both mother and child. We are committed to increasing awareness to screen for devastating diseases such as fetal and neonatal alloimmune thrombocytopenia (FNAIT). I encourage you to put preventative testing and screening for diseases like breast cancer and #FNAIT at the forefront of your mind this May and beyond. Read more from CNBC: https://lnkd.in/ewjeDM36
Get screened for breast cancer starting at age 40, new recommendations say
nbcnews.com
-
The 2024 Yale Innovation Summit is officially underway! Details on where you can catch our co-founders on-site this week are below – if you’re attending, stop by and learn about the future of #rarediseases. 🔬May 29 (1:30-3:40 pm ET): Biotech showcases in the OC Marsh Auditorium with co-founder and CEO, Stephen Uden. 🦠May 30 (3:30-4:30 pm ET): New Opportunities in Rare Disease’ with co-founder Martin Mackay, Ph.D., alongside Lon Cardon, Ph.D., Matthew Klein, MD, MS, FACS , Nina Kjellson, Michele Spencer-Manzon, MD, and moderator David Scheer on May 30 from 3:30-4:30 pm ET. Hope to see you there! #YaleInnovation2024 🧬
Similar pages
Browse jobs
Stock
RLYB
NASDAQ
20 minutes delay
$1.30
-0.03 (-2.256%)
- Open
- 1.34
- Low
- 1.29
- High
- 1.37
Data from Refinitiv
See more info on